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Paralleling the ﬁrst 30 years of the Journal of Hepatology we have
witnessed huge advances in our understanding of liver disease
and physiology. Genetic advances have played no small part in
that. Initial studies in the 1970s and 1980s identiﬁed the strong
major histocompatibility complex associations in autoimmune
liver diseases. During the 1990s, developments in genomic tech-
nologies drove the identiﬁcation of genes responsible for
Mendelian liver diseases. Over the last decade, genome-wide
association studies have allowed for the dissection of the genetic
susceptibility to complex liver disorders, in which also environ-
mental co-factors play important roles. Findings have allowed
the identiﬁcation and elaboration of pathophysiological process-
es, have indicated the need for reclassiﬁcation of liver diseases
and have already pointed to new disease treatments. In the
immediate future genetics will allow further stratiﬁcation of liver
diseases and contribute to personalized medicine. Challenges
exist with regard to clinical implementation of rapidly develop-
ing technologies and interpretation of the wealth of accumulating
genetic data. The historical perspective of genetics in liverJournal of Hepatology 20
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by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Over the last 30 years, genetics has enhanced our understand-
ing and management of liver disease (Table 1). The fundamen-
tal technologies available for genetic analysis encompass
positional cloning of unknown disease genes, simple gene tests
for known single nucleotide variants (SNV), genome-wide
association studies (GWAS) that compare genotype frequencies
across the whole genome between cases and controls to
identify unknown genetic risk factors, and next-generation
sequencing (NGS) of selected genes, all exons, or the whole
genome in individual patients.
To illustrate the developments and opportunities of these
genetic methods and technologies, we here pose and address ﬁve
key questions that should help students, researchers, and health
care professionals to understand the strides in the genetics of liv-
er disease. Our answers cover both historical aspects and indicate
how the advances in our understanding have led to a rapidly
developing framework for diagnostic and therapeutic strategies.
Rather than a comprehensive representation of the complete
genetics of liver disease (for which comprehensive reviews can
be found [41]), we aim to present the reader with key examples
of the current state of the ﬁeld and our associated reﬂections. We
focus on germline mutations and deliberately omit the utility of
genomics in the management of hepatocellular carcinoma and
cholangiocarcinoma, which is also covered elsewhere [42] and
in this special issue.Has genetics improved our understanding of the pathophysio-
logy of liver diseases?
The ﬁrst genes of monogenic diseases with predominant liver
phenotypes that were mapped and cloned were the Wilson
disease gene ATP7B (1993) and the haemochromatosis gene HFE
(1996) (Table 1; Fig. 1). The Wilson disease gene was localized15 vol. 62 j S6–S14
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Fig. 1. Scope of review. With an emphasis on the developments of the last
30 years, the present article aims to discuss the implications of genetic studies in
liver diseases onto relevant aspects of research and clinical hepatology. Topics
covered range from descriptions of basic pathophysiology to practical aspects of
diagnosis and treatment of the individual patient. The examples have been
selected to illustrate the utility of genetic tools for speciﬁc aspects of clinical
practice. For details, see text; for gene name abbreviations, see http://www.ncbi.
nlm.nih.gov/gene/.
Key Points 
Different liver diseases are at different stages of the following 
sequence of steps:
• The first genetic discoveries identified the major loci for 
Mendelian diseases
• Numerous studies have identified susceptibility to 
complex diseases
• All diseases are actually complex with multiple genes 
contributing to the phenotype
• With the identification of different underlying genetic 
contributors to disease those diseases are being 
reclassified
• A better understanding of genetic aetiology will suggest 
new modes of treatment for disease
• A complete understanding of all the contributors to 
a individual’s disease will allow personally tailored 
treatment
JOURNAL OF HEPATOLOGYby linkage disequilibrium and haplotype analysis in more than
100 families [8]. Functional studies demonstrated that it encodes
a P-type ATPase gene with metal binding regions similar to those
found in prokaryotic heavy metal transporters [9]. Building on
this discovery, subsequent studies were able to determine vast
aspects of previously unknown aspects of copper transport and
the pathophysiology of Wilson disease [43]. Using a similar
strategy three years later, the HFE gene in the extended major
histocompatibility complex (MHC) was shown to be mutated in
patients with autosomal-recessive haemochromatosis [10].
Furthermore, additional types of non-HFE hereditary haemochro-
matosis were subsequently described, linked to mutations in the
ferroportin gene (SLC40A1) [17,18], the transferrin receptor 2
gene (TFR2) [19], the hepcidin gene (HAMP) [20] and the hemoju-
velin gene (HJV) [21], respectively. These genetic discoveries
jointly paved the way for the full characterization of hepatic iron
metabolism and its regulators [44], allowing for dissection of
mechanisms responsible for the development of liver disease in
the presence of detected mutations.Table 1. Present day technologies involved in the detection of disease relevant geneti
sequencing techniques (targeting genes, the coding regions of the genome [exome] or
number variant detection. Cost (price) and the availability of relevant bioinformatic tools
any observed trait.
Mendelian diseases
Degree of heritability Relative sibling risk increased >200-1000 t
compared with general population risk
Technology preferences Whole-exome and whole-genome sequenc
Study design Linkage analysis, in silico candidate varian
prioritization, functional assessments of dis
Key challenges Large number of candidate variants makes
identification difficult, mechanistic support 
needed and may require extensive studies
Journal of Hepatology 20The mutation proﬁle of disease genes varies. Hereditary
haemochromatosis is most often caused by a predominant
founder mutation (p.C282Y) which accounts for approximately
95% of patients [45]. Wilson disease shows a different genetic
proﬁle, with extensive allelic heterogeneity with more than 500
mutations described in the ATP7B gene to date. For this reason,
genetic testing in haemochromatosis is undertaken via targeted
genotyping of the predominant variants (always starting with
p.C282Y), whereas in Wilson disease there is a need for gene
sequencing and variant analysis to obtain genetic support for
the diagnosis.
The ﬁrst GWAS in hepatobiliary diseases was performed for
gallstone disease and conﬁrmed the candidacy of the hepatobil-
iary cholesterol transporter ABCG5/G8 as a major susceptibility
gene for gallstones worldwide, with p.D19H representing the
likely causal single nucleotide polymorphism (SNP) [22,46].
Other rare loss-of-function SNVs in this transporter had been
identiﬁed previously, in individual patients, to underlie the
monogenic disease sitosterolemia, which is characterized by
unrestricted intestinal absorption of both cholesterol and
phytosterols such as sitosterol [47]. The adjacent, oppositely ori-
ented ABCG5/G8 genes encode two ATP-binding cassette (ABC)
hemitransporters that are localized in the apical membranes of
enterocytes and hepatocytes. The case also illustrates ac variation. These genomic technologies are principally deriving from a variety of
the whole genome) and microarrays for genome-wide single nucleotide or copy
also need considerations in making the ideal selection of method for investigating
Complex diseases
imes Relative sibling risk increased  
2-20 times compared with general population risk
ing Single nucleotide polymorphism arrays
t filtering and 
ease variants
Genome-wide case-control association analysis
 conclusive 
for causality 
Low effect size of relevant variants means large 
numbers of patients and controls are needed to 
establish robust findings (typically thousands)
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Table 2. Four decades of genetic discoveries in liver diseases. The table lists landmark articles on the genetic susceptibility to liver diseases. The listing is not
comprehensive, but serves to show the development of the ﬁeld over the timespan of the last 40 years. The attention of the ﬁeld has shifted from the detection of the major
histocompatibility complex (MHC) associations in autoimmune liver diseases via the elucidation of the genetics of Mendelian phenotypes to the broader dissection of the
genetics of complex liver diseases by genome-wide association studies (GWAS).
Year Landmark genetic publication References
1972 MHC associations in autoimmune hepatitis [1]
1979 MHC associations in primary biliary cirrhosis [2]
1982 MHC associations in primary sclerosing cholangitis [3]
1989 CFTR in cystic fibrosis [4]
1992/95 UGT1A1 in Gilbert and Crigler-Najjar syndromes [5-7]
1993 ATP7B in Wilson disease [8, 9]
1996 HFE in haemochromatosis (type 1) [10]
1997 ABCC2 in Dubin-Johnson syndrome [11]
1997 JAG1 in Alagille syndrome [12,13]
1998 ATP8B1 in PFIC (type 1) [14]
1998 ABCB11 in PFIC (type 2) [15]
1998 ABCB4 in PFIC (type 3) [16]
2001 SLC40A1 (ferroportin) in haemochromatosis (type 4) [17,18]
2002 TFR2 in haemochromatosis (type 3) [19]
2003 HAMP in haemochromatosis (type 2B) [20]
2004 HJV in haemochromatosis (type 2A) [21]
2006 NOTCH2 in Alagille syndrome [12]
2007 ABCG8 in gallstone disease (GWAS) [22]
2008 PNPLA3 in non-alcoholic fatty liver disease (GWAS) [23]
2008 First GWAS on genetic factors associated with plasma liver enzyme activities [24]
2009 First GWAS in primary biliary cirrhosis [25]
2009 MHC associations in flucloxacillin DILI (GWAS) [26]
2009 MHC associations in HBV clearance (GWAS) [27]
2009 IL28B in HCV treatment response (GWAS) [28]
2009 IL28B in spontaneous HCV clearance (GWAS) [29]
2009 Genetic modifiers for CFTR-associated liver disease [30]
2010 PNPLA3 in alcoholic liver disease [31]
2010 First GWAS in primary sclerosing cholangitis [32]
2010 ITPA in ribavirin-induced anaemia (GWAS) [33]
2010 First GWAS in hepatitis B-related hepatocellular carcinoma (GWAS) [34]
2011 MHC associations in amoxicillin-clavulanate DILI (GWAS) [35]
2012 OATP1B1 and OATP1B3 in Rotor syndrome [36]
2012 First GWAS on liver fibrosis in chronic HCV infection [37]
2014 First GWAS in autoimmune hepatitis [38]
2014 TJP2 in PFIC (type 4) [39]
2014 MHC associations in hepatitis B vaccine response (GWAS) [40]
DILI, drug-induced liver injury; HBV, hepatitis B virus; HCV, hepatitis C virus; PFIC, progressive intrahepatic cholestasis. For gene name abbreviations, see http://www.ncbi.
nlm.nih.gov/gene/.
Reviewfundamental difference between risk factors in monogenic vs.
polygenic/complex traits (Table 2). For sitosterolemia, the SNVs
appear to be sufﬁcient to cause the observed phenotype. For risk
alleles of SNPs detected by GWAS (that have an odds ratio of
approximately 2), interacting genetic and environmental factors
are required for gallstone development [46,48,49].
GWAS for autoimmune liver diseases have led to the detection
of several dozen risk genes in primary biliary cirrhosis (PBC) [25],
primary sclerosing cholangitis (PSC) [32,50] and recently,
autoimmune hepatitis (AIH) [37]. With few exceptions, the
detected risk loci overlap with those of other autoimmune and
immune-mediated diseases (Fig. 2) [51–53]. This means that
the majority of the genetic risk factors for these phenotypesS8 Journal of Hepatology 20involves an increasing susceptibility to autoimmunity rather than
liver affections per se. A large fraction of the risk loci and the
strong MHC associations found in both PBC, PSC, and AIH point
to the pathophysiological importance of adaptive immune
responses [46]. The overall genetic contribution to disease
susceptibility in PBC, PSC, and AIH is relatively low, with the
current risk gene pool representing less than 10% of the overall
disease liability [51,52]. Larger studies will increase this fraction,
but more than 50% of the susceptibility to these diseases is still
likely to be of an environmental origin.
Individual whole-exome sequencing (WES) has been
successfully used to identify unknown genetic variants for
inherited diseases or conditions of indeterminate aetiology such15 vol. 62 j S6–S14
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Fig. 2. Genetic architecture of complex diseases. Genetic studies have unambiguously pinpointed a role for adaptive immune responses in causing primary sclerosing
cholangitis (PSC, panel A). The overall genetic architecture of PSC shows similar features as prototypical autoimmune diseases (e.g., type 1 diabetes, panel C) and only a
partial overlap with that of inﬂammatory bowel disease (panel B). Diseases caused by distinct exogenous factors (e.g., drug-induced liver injury, celiac disease, panel D)
show a similar genetic architecture, where a strong association with genes in the major histocompatibility complex (MHC, plotted in red) is the deﬁning feature. Plots
derived from data in reference [52]; the X axis shows chromosomal location, the Y axis shows association statistic for investigated variants (individual dots).
JOURNAL OF HEPATOLOGYas acute liver failure in children [54]. Recently this has been
illustrated in two families with unsuspected mitochondrial
hepatopathies, where WES of germline DNA indicated homozy-
gous mutations in MPV17 and SERAC1 as causative in paediatric
cases of acute liver failure [55]. In fact, liver disease-targeted
re-sequencing of genes has been implemented in several liver
centres and we believe that it ultimately will be fully integrated
into care and get a ﬁrm place in the diagnostic evaluation of
patients with unexplained liver disease, in particular in the set-
ting of a strong family history of similar afﬂictions. Due to the
massive amounts of data being generated, establishing the patho-
physiological connection for detected variants within a clinically
relevant time frame remains a major challenge.Is genetics helpful for the deﬁnition of liver diseases and disease
subtypes?
Fifty years ago, Byler disease was ﬁrst described in an Amish
kindred [56]. The same disorder in non-Amish populations was
termed Byler syndrome, which represented a heterogeneous
group of autosomal-recessive liver diseases characterized by
early onset of cholestasis that progresses to hepatic ﬁbrosis, cir-
rhosis, and end-stage liver disease often before adulthood. In
the past two decades basic research teams identiﬁed and cloned
hepatobiliary transport proteins that are involved in the apical
uptake and canalicular secretion of bile acids as well as otherJournal of Hepatology 20endo- and xenobiotics (Fig. 3) [57,58]. The landmark study by
Smit et al. [59] demonstrated that homozygous disruption of
the murineMdr2 P-glycoprotein gene, now known as Abcb4, leads
to a complete absence of phosphatidylcholine from bile and
chronic cholangiopathy. Massive gene ampliﬁcation and rear-
rangements also cause hepatocellular cancer in this model [60].
Studies in humans demonstrated that the phenotypic conse-
quences of mutations of the orthologous human gene MDR3/
ABCB4 range from neonatal cholestasis to progressive familial
intrahepatic cholestasis (PFIC) and cirrhosis in adults [16,61];
they can also result in intrahepatic cholestasis of pregnancy
(ICP) [62] as well as intrahepatic and gallbladder cholesterol cho-
lelithiasis, termed low phospholipid-associated cholelithiasis
(LPAC) syndrome [63,64].
The related gene ABCB11 encodes the bile salt export pump
(BSEP) and was shown to be mutated in consanguineous families
with PFIC but generally low serum c-glutamyl transferase
activities [15,65]. In contrast, patients with Byler disease and
others were shown to carry mutations in the ATP8B1 (FIC1) gene
[14,66] which encodes a P-type ATPase that ﬂips
phosphatidylserine from the outer to the inner leaﬂet of the
hepatocanalicular membrane, thereby maintaining membrane
integrity [67]. Studies comparing the phenotypic presentation
and progression between BSEP and FIC1 deﬁciencies [68,69]
reported that the former patients were more likely to develop
neonatal cholestasis and manifested more severe hepatobiliary
disease (as indicated by higher serum ALT activities and bile salt15 vol. 62 j S6–S14 S9
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Fig. 3. Major molecular proteins involved in genetic cholestasis. Multidrug
resistance-associated protein 2 (MRP2) transports organic anion (OA) conjugates,
including bilirubin, and is mutated in Dubin–Johnson syndrome. Bile salt export
pump (BSEP) is the major bile acid (BA) transporter. Multidrug resistance 3
(MDR3) ﬂops phosphatidylcholine (PC) and familial intrahepatic cholestasis
protein 1 (FIC1) ﬂips aminophospholipids (AL). TJP proteins are involved in
maintaining the stability of integral tight junction proteins, including claudins.
Reviewconcentrations) as well as cholelithiasis and hepatocellular
carcinoma [60,70], while the latter showed greater evidence of
extrahepatic manifestations (malabsorption, pancreatitis, pneu-
monia, hearing loss). Most recently a fourth PFIC gene has been
described. Mutations in TJP2, encoding tight junction protein 2
(or zona occludens 2), were shown to lead to early onset liver dis-
ease [38]. In fact, although all four genes were found to underlie
PFIC, each has now been shown to be responsible for spectra with
severe and mild phenotypes [22,66,71–73].
Genetic studies have also clariﬁed the pathophysiology of
Dubin–Johnson and Rotor syndrome, which are due to mutations
of hepatocellular bilirubin transporter genes: mutations of the
human canalicular multispeciﬁc organic anion transporter gene
(now termed ABCC2) underlie Dubin–Johnson syndrome [11],
whereas combined deﬁciency of the basolateral organic anion
transporting polypeptide (OATP) 1B1 and OATP1B3 results in
Rotor syndrome by interrupting conjugated bilirubin uptake into
the liver [36]. In contrast, mutations in the promoter or exons of
the bilirubin conjugating enzyme UGT1A1 underlie hereditary
unconjugated hyperbilirubinaemia, with the frequent and benign
Gilbert–Meulengracht syndrome being due to a common pro-
moter mutation; more severe mutations cause Crigler–Najjar
syndrome in childhood. Unconjugated hyperbilirubinaemia is a
known risk factor for gallstone disease, explaining the robust
genetic association of the Gilbert–Meulengracht variant and
cholelithiasis [74,75].S10 Journal of Hepatology 20In 1997, Oda et al. [76] and Li et al. [77] demonstrated that
another hereditary cholestatic liver disease, Alagille syndrome,
is caused by mutations in the human homolog of Jagged-1
(JAG1), which encodes a ligand in the Notch signalling pathway.
Alagille syndrome is a rare autosomal-dominant disease with
patients showing not only paucity of intrahepatic bile ducts,
but characteristic dysmorphic facies and cardiac anomalies, nota-
bly peripheral pulmonary stenosis, along with posterior embry-
otoxon and notched or butterﬂy vertebrae as well as failure to
thrive. In less than 1% of patients, the disease is caused by
NOTCH2 mutations [12,13], and the phenotypes are now known
to be modiﬁed by other genes such as thrombospondin 2 [78].How might genetics contribute to the classiﬁcation of liver
diseases?
Usually fatty liver disease is attributed to alcohol or metabolic
stress, resulting in the terms alcoholic steatohepatitis (ASH) or
non-alcoholic steatohepatitis (NASH) [79]. However, ASH may
present as acute alcoholic hepatitis or chronic steatohepatitis,
and both alcohol and environmental factors (over-nutrition,
physical inactivity) can contribute to liver disease. In addition,
chemotherapy and other drugs might also cause steatohepatitis.
Interestingly, only a subgroup of patients (10–20%) who drink
alcohol and/or are overweight develop severe steatohepatitis,
advanced ﬁbrosis, and cirrhosis. Since 2008, GWAS-based studies
have led to the identiﬁcation of a major genetic determinant of
fatty liver and steatohepatitis as well as progression to ﬁbrosis,
cirrhosis, and hepatocellular cancer. Romeo et al. [23] identiﬁed
the amino acid substitution p.I148M of the lipid droplet-associat-
ed trigylceride lipase PNPLA3 (also termed adiponutrin) to confer
susceptibility to non-alcoholic fatty liver disease. It appears also
to be the major genetic risk factor aggravating alcoholic liver
disease [31,80]. This SNP is highly prevalent in European popula-
tions (risk allele frequency 21–28%) and confers a 3-fold risk for
liver disease and NASH as well as a 12-fold risk for hepatocellular
cancer in comparison to healthy controls [81]. The effect is mod-
iﬁed by other genetic risk factors such as TM6SF2 p.E167K [82]
but the population-attributable risk for fatty liver disease is high-
est for PNPLA3 p.I148M [81]. Therefore, we have proposed to use
this novel genetic information to deﬁne a group of patients with
fatty liver disease in whom the susceptibility gene PNPLA3
appears to be a major driver of disease progression, often in com-
bination with ethanol and Western diet but also without, hence
the suggested name PNPLA3-associated steatohepatitis
(‘‘PASH’’) [83]. Although the PNPLA3 risk genotypes confers a high
risk of NASH, the patients appear to be sensitive to the beneﬁcial
effects of lifestyle modiﬁcation and dietary intervention should
be encouraged to do so [84,85].
Common, conserved, aetiopathogenic pathways have been
proposed across diseases, often related to failed resolution of
responses to infections or stress and damage caused by the
patient’s immune system [86]. Recently a new cytokine-based
taxonomy has been proposed for chronic inﬂammatory diseases,
comprising tumour necrosis factor (TNF)-a, interleukin (IL)-1,
IL-6, IL-17, and IL-23 associated diseases, which are characterized
by inﬂammation in different organs such as gut, skin, joints and
brain [87]. Preclinical studies and randomised controlled trials
with targeted cytokine intervention in humans indicate the exis-
tence of a cytokine hierarchy that was used to deﬁne these novel15 vol. 62 j S6–S14
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disease groups. For example, IL-1 is predominantly involved
when inﬂammasome activation is the dominant mechanism of
inﬂammation, a situation that arises in gout and rare genetic
autoinﬂammatory syndromes such as cryopyrin-associated peri-
odic syndrome and familial Mediterranean fever. Hence, these
disorders might be grouped together as IL-1-associated diseases.
The fact that the accumulation of metabolic substrates such as
urate, cholesterol, ceramide, and glucose can trigger the
inﬂammasome provides the rationale for current therapeutic tri-
als targeting IL-1 in metabolic liver diseases such as fatty liver
disease and alcoholic hepatitis.
The excessive pleiotropy of autoimmune risk variants provides
another example of the imperfect relationship between tradition-
al disease classiﬁcations on one side and molecular entities on the
other. For autoimmune liver diseases, there are shared features
(e.g. SH2B3 variants associating with PBC, PSC and AIH) as well
as pathways predominantly associating more on either side of
the spectrum (e.g. IL-2-related associations in PSC and IL-12-
related associations in PBC) [53]. The importance of these obser-
vations as for clinical implementation is still not clear and it is
important to acknowledge that phenomenology by means of
clinical manifestations (e.g. sclerosing cholangitis) or traditional
biochemistry (including autoantibodies) may still represent key
biology upon which these apparently diverse associations
converge. In Crohn’s disease, several susceptibility genes
(ATG16L1, NOD2, and IRGM) appear to involve Paneth cell dysfunc-
tion as a common denominator for ileal disease affection [88],
exemplifying how the clinical features may still be as valid a
representation of key pathophysiology as a gene based classiﬁca-
tion. As such, data on genetic background and genetic risk factors
are likely never to replace disease deﬁnitions by medical history
and clinical investigations, butmay provide another layer of infor-
mation with a strong potential to reﬁne patient management.Genetic 
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Fig. 4. Distinguishing Mendelian from complex liver diseases. For complex
phenotypes, the contribution from genetics to overall disease liability is limited
(typically less than 50%). In addition, only a fraction (typically 10–20%) of the
genetic susceptibility is known. In both Mendelian and complex disease
manifestations the gene ﬁndings serve clues as to the underlying patho-
physiology. Only for the case of Mendelian liver affections do genetic ﬁndings
have clinically useful predictive power. Modiﬁed from [109].Does genetics affect the treatment of liver disease?
GWAS studies have led to the identiﬁcation of variants in the
IL28B gene encoding interferon (IFN)-k3 that are associated with
response to antiviral IFN-based therapy in patients with chronic
hepatitis C virus (HCV) infection [28]. Additional studies showed
that these polymorphisms are linked with a diplotype of the
previously unknown IFN-k4 (IL29) [89] that is induced by HCV
and leads to an IFN-stimulated gene expression; a two-base pair
insertion or the mutation p.P70S results in loss or reduced activity
of IFN-k4, respectively [90,91]. Of note, the mechanisms involving
the IFN-k regulatory axis are not HCV-speciﬁc but also determine
the outcome of infections with other viruses such as herpes sim-
plex virus type 1 (HSV-1) infection causing vesicular oral and skin
lesions, keratitis, or encephalitis [92]. This opens new insights and
suggests integrative studies investigating the interaction between
the innate immune response, including IFN-k4, and T cells [93]. In
light of the new potent direct antiviral agents, the clinical rele-
vance of IL28B and IL29 gene variation has diminished, but it also
determines spontaneous clearance of HCV infection [29,94]. Of
note, the gene variants are also associated with the severity of
viral hepatitis, even with some contrasting ﬁndings [95],
highlighting that the effects of gene polymorphisms can be
pleiotropic, increasing the complexity of clinical phenotype,
genetic background, and environmental factors [96]. Along the
same line, variants of the NASH risk factors PNPLA3 and TM6SF2
have also been shown to modulate cardiovascular risk [97,98].Journal of Hepatology 20Drug-induced liver injury (DILI) represents a clinically diverse
spectrum. Hyman J. Zimmerman discriminated direct and
idiosyncratic hepatotoxicity [99]. Whereas direct hepatotoxic
drugs lead to dose-related liver injury that is reproducible in ani-
mal models, idiosyncratic liver injury shows an unpredictable
outcome and is rare. The clinical manifestation of idiosyncratic
DILI is acute hepatitis, and to date the diagnosis has been made
by exclusion [100]. Idiosyncratic DILI cases are most often caused
by antibiotics and generic drugs that have been approved decades
ago. In terms of aetiology, DILI is not a single, uncommon disease
but rather many, rare diseases converging on a similar presenta-
tion of immune-mediated liver injury. A GWAS for a common
type of DILI caused by amoxicillin-clavulanate exposure showed
the strongest ﬁnding in the MHC region, with signals localizing
to human leukocyte antigen (HLA) class I and II genes.
Although the respective HLA genotypes (HLA-A*02:01 and
DQB1*06:02) have limited utility as predictive biomarkers
because of low positive-predictive values, they can post hoc serve
to assess causality in individual severe cases. Furthermore, the
MHC associations point to the involvement of adaptive immuni-
ty, likely representing immune reactions to the drug itself, to
drug metabolites, or to drug-generated neoantigens (protein
adducts), any of which can trigger immunity in otherwise suscep-
tible individuals. Such mechanisms might even be amendable to
early treatment with steroids or other types of immunosuppres-
sion [101,102]. To date, additional GWAS have indicated only a
limited contribution of common genetic variants outside of the
MHC to risk of DILI [103].What are the future hurdles and perspectives for translation
of genetic research into clinics?
The best strategy for the transformation of the large number of
genetic ﬁndings into novel therapeutic opportunities for complex
liver diseases is not known. Almost 40 years after the discovery of
the gene defect in cystic ﬁbrosis [4], genetic information provides
information on the future disease course of individual patients,
and variant-speciﬁc treatment is being deployed [104]. In PBC,
an attempt was made to target the IL-12-related genetic ﬁndings
by ustekinumab, a monoclonal antibody which targets the p40
subunit of IL-12 and IL-23. The study was terminated due to lack
of efﬁcacy (https://clinicaltrials.gov/ct2/show/NCT01389973)
and serves to exemplify the point that genetic ﬁndings do not15 vol. 62 j S6–S14 S11
Review
necessarily identify therapeutic targets. It is also clear that for the
complex phenotypes, genetic ﬁndings are also not useful for dis-
ease prediction (genetic testing) (Fig. 4) [105,106]. Both these
aspects pertain to the lack of knowledge on interacting environ-
mental (and other genetic) factors and the genuine function of
the relevant gene products. In our opinion, the main purpose of
genetics in complex phenotypes is to specify experimental
research into disease pathophysiology (‘‘pathway detection’’). A
challenge in forming relevant hypotheses for experimental and
translational research following the application of GWAS is that
most of the research into the relevant biology has been
performed without the prior knowledge of the liver disease asso-
ciations. Surprising and novel insights are likely to arise from cor-
rectly designed experiments on relevant models and human
material, exempliﬁed by the unravelling of IL-29 in HCV clear-
ance [89]. These efforts are now urgently needed and will be
the source of genuine clinical relevance and therapeutic applica-
tions – which so far are lacking for the gene ﬁndings per se.
Evident from the above discussions, for monogenic and even
oligogenic liver diseases, genetic testing is already relevant.
Here, the obstacles to clinical implementation are that of access
to technology and associated expertise. WES has now been used
extensively, and successfully, for research. Whole-genome
sequencing (WGS) has advantages and disadvantages in compar-
ison to WES. There is complete genomic coverage, sample prepa-
ration is easier, and there is less bias in the generated sequence
[107]. Yield, in terms of a conclusive diagnosis is therefore higher
[108]. The costs of WGS are decreasing rapidly, but major hurdles
to widespread use of either technique for routine diagnostics
remains in the interpretation of data. A number of commercial
and mainly research-oriented software packages are now avail-
able, but none are perfect and there is no integration with the
regular patient information systems. The most critical issue
remains however the huge number of variants found in each indi-
vidual. Within these variants lie not only the ‘‘cause’’ of
Mendelian diseases, but, as discussed above, disease-modiﬁers
and predictors of treatment response. Since disease severity
varies even for ‘‘classic’’ monogenic liver diseases (Table 1), it is
difﬁcult to tell the difference between a susceptibility allele and
a disease modiﬁer, and ultimately every disease is more or less
complex (Fig. 4). We simply do not yet have the knowledge and
tools to implement most of the new data in clinical practice.
The only way we will be able to approach this information, and
thereby get closer to a vision of ‘‘personalized medicine’’, is
through large cohort studies incorporating detailed clinical and
molecular phenotyping alongside the WGS data. Such efforts
are needed now more than ever.Conﬂict of interest
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